Skip to main content

Radius Health provides promising data

Raduis Health Inc. (Nasdaq: RDUS) provided promising updated data from a Phase 1 005 clinical study of elacestrant to treat breast cancer. Shares of the biopharmaceutical surged $4.19 to close at $31.60.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.